Are you struggling to find reliable antibodies against G-protein-coupled receptors (GPCRs) for your scientific or clinical projects? At ProteoGenix, we understand the challenges of developing high-quality GPCR antibodies. That’s why we use advanced techniques and rigorous quality control testing to ensure the reproducibility and specificity of every GPCR antibody we customize. From antigen design and production to antibody generation and purification, our team of experts works closely with you through predefined project milestones to ensure that your antibody is built on time and on budget. Contact us today to see how our custom monoclonal antibodies can help you achieve your research goals.
Diverse custom antibody generation strategies
Flexible strategies to meet diverse needs and budgets, including phage display, hybridoma technology, and single B-cell screening methods.
Binders guaranteed
We guarantee at least 3 unique binders to your antigen.
IP free
You get full ownership of the antibody sequences generated!
Take advantage of unique libraries
Access our proprietary cancer and auto-immune human phage display libraries. You will find them anywhere else!
Pre-built phage display libraries.
Save time and money by selecting one of our existing libraries from human (including our cancer and/or auto-immune libraries), rabbits, camelids, dogs.
Naïve or immune library
Choose from our naive libraries or develop your own phage display immune library.
Unmatched GPCR Antigen Production Capability
We immunize hosts with natively folded GPCRs in micelles, nanodiscs, or whole cells that express your GPCR of interest – resulting in high-quality, natively folded GPCRs.
Constant communication
We update you on every project milestone allowing you to evaluate our progress so we stay on target and on budget.
Fully human antibodies available
Expertise in developing fully human clinical antibodies without humanization, unmatched by most suppliers
Safe and Flexible Antibody Development
Secure your antibody investment with milestone-based services for complex and high-risk projects.
Strict Quality Control Testing
Our custom GPCR antibodies undergo rigorous quality control standards to ensure they do not cross-react with other conserved GPCRs giving you confidence in your research.
ProteoGenix uses one of three different antibody engineering strategies to make custom monoclonal antibodies that bind GPCR antibodies. These include creating hybridoma cell lines, isolating anti-GPCR-specific B-cells, and screening for specific anti-GPCR antibodies using phage display. ProteoGenix can assist you in determining which method is best suited to your project and budget.
Antibody phage display is a method that involves obtaining peripheral blood mononuclear cells (PBMCs) from either immunized animal hosts (immune libraries) or unimmunized hosts (naïve libraries). After PBMC collection, the antibody gene segments are converted into cDNA and cloned into a phagemid to create an antibody-phage fusion protein, which displays the antibody on the outer surface of the bacteriophage. Next, the target antigen is cloned and immobilized to a surface so the antibody on the phage surface can bind the immobilized antigen, a process called biopanning. Once the antibody binds to the antigen, the DNA inside the bacteriophage, containing the antibody-related genes, is extracted, sequenced, and expressed to confirm its efficacy. Learn more about our antibody phage display service.
Antigen procurement or design and production
Library screening and biopanning
ELISA screening of single phage binders
DNA extraction & antibody sequencing
Antibody humanization
Recombinant antibody production
Therapeutic antibody production
Stable Cell Line Development
ADC development
Bispecific Antibodies
Antibody phage display is a valuable technique for producing monoclonal antibodies that target cytotoxic antigens, rare antigens (or epitopes), or antigens with low immunogenicity. In addition, antibody phage display is particularly useful for making custom antibodies used clinically because of ProteoGenix’s flexible cancer and autoimmune human phage display libraries. These new libraries offer our clients the flexibility to quickly, identify unique human antibodies that bind their GPCR of interest cost-effectively. If your biomedical research lab or pharmaceutical company aims to expedite human immunotherapy projects aimed at treating cancer, autoimmunity, or other diseases, then antibody phage display technology is the ideal choice.
Antibody phage display is a powerful technique for custom antibody generation because there is no species limitation. Whether you’re interested in making unique anti-GPCR antibodies to perform in a specific biomedical research experiment or you need to build complex immunotherapy, ProteoGenix can meet your needs. Our team can immunize rabbits, mice, and even camelids to generate custom anti-GPCR antibodies that target your favorite GPCR with precision. We can also screen your GPCR of interest using our pre-built naive human autoimmune and cancer libraries to quickly identify antibodies that bind rare GPCR epitopes. Our comprehensive approach ensures that you receive high-quality, fully customized antibodies for your specific research needs.
Once we discover at least three different antibodies that bind your GPCR with precision, we will deliver the antibody DNA (cDNA) sequences to you. These sequences become your intellectual property (IP) giving your institution or company the following benefits:
We can adapt your monoclonal phage display antibody into a bispecific antibody or conjugate it to cytotoxic drugs (ADC antibody) to target diseased tissue. We can also adapt your custom GPCR antibody for diagnostic applications such as ELISA, flow cytometry, or clinical imaging.
Generating your custom anti-GPCR antibody by making a hybridoma cell line is a great way to make anti-GPCR antibodies that bind with high affinity. The first step in producing a hybridoma cell line involves immunizing mice or rats with the GPCR antigen. Next, we collect splenocytes from the immunized mice or rats and fuse the appropriate B-cells with a myeloma cell line. We select the hybrid cells by screening the supernatant for antibodies that bind the target antigen by ELISA. Lastly, we subject the positive binders to limited dilutions to isolate individual cells and expanded them into colonies. We then screen each colony and further verify their potential to bind antigens by ELISA. The entire process takes 10 weeks from start to finish. Read more about ProteoGenix’s hybridoma technology.
Immunization
Cell Fusion
Hybridoma Selection and Screening (Polyclonal Stage)
Isolation of Cell Clones
Our B-cell screening process follows a rigorous three-step procedure that ensures the production of monoclonal antibodies with exceptional affinity. To begin, we immunize rodents with purified antigens, which we carefully assess using SDS-PAGE. This process lasts for 6 to 8 weeks and involves our optimized immunization protocol, which consists of 4 to 6 rounds of injections. The next step involves a 2–3-week process of sorting and screening B-cells, where lymphocytes are isolated from the PBMC compartment and spleen of immunized rodents. These B-cells are then cultured in vitro, and the supernatants are analyzed via ELISA to identify the presence of antibodies that bind to the target antigen. The top-performing antibodies are then sequenced, cloned, and expressed in XtenCHO cells, followed by further ELISA screening to confirm the production of high-quality monoclonal antibodies. Learn more about ProteoGenix’s B-cell screening and isolation methods.
FACS Sorting + ELISA screening
Positive Clones Sequenced and Expressed
Screening of the antibodies produced
Table 1: Anti-GPCR Antibody Production Method Pros and Cons